Two distinct CD28-specific mAb were used in treatment of active or adoptive transfer (AT)-
experimental autoimmune neuritis (EAN):“superagonistic” JJ316 activates T cells without T
cell receptor (TCR) occupancy, and conventional JJ319 activates T cells only in the
presence of TCR-stimulation. Treatment with JJ316 during induction phase of active and
adoptive-transfer experimental autoimmune encephalomyelitis (AT-EAN) dramatically
reduced disease severity and improved nerve function as revealed by electrophysiology …